Stress axis dysfunction: A common finding in schizophrenia and the metabolic syndrome?

Modern Trends in Pharmacopsychiatry

Volumn 26, Issue , 2009, Pages 82-89

  Afzal, Natasha ^a   Thakore, Jogin ^a  

^a St Vincent's Hospital Ireland   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

BODY FAT; HIPPOCAMPUS; HUMAN; HYPERCORTISOLISM; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; INSULIN RESISTANCE; ISCHEMIC HEART DISEASE; MENTAL DISEASE; METABOLIC DISORDER; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; REVIEW; SCHIZOPHRENIA; STRESS;

EID: 67649988391     PISSN: 16622685     EISSN: 16624505     Source Type: Book Series    
DOI: 10.1159/000189776     Document Type: Review

References (58)

1. Charmandari E, Kino T, Souvatzoglou E, Chrousos GP: Pediatric stress: hormonal mediators and human development. Horm Res 2003;59:161-179.
2. Tsigos C, Chrousos GP: Hypothalamic-pituitary-adrenal axis, neuroendocrine factors and stress. J Psychosom Res 2002;53:865-871.
3. Gil-Ad I, Dickerman, Z, Amdusky S, Laron Z: Diurnal rhythm of plasma beta endorphin, cortisol and growth hormone in schizophrenics as compared to control subjects. Psychopharmacology 1986;88:496-499.
4. Whalley LJ, Christie JE, Blackwood DH, Bennie J, Dick H, Blackburn IM, Fink G. Disturbed endocrine function in the psychoses. I. Disordered homeostasis or disease process? Br J Psychiatry 1989;155:455-461.
5. Brier A, Buchanan RW: The effects of metabolic stress on plasma progesterone in healthy volunteers and schizophrenic patients. Life Sci 1992;51:1527-1534.
6. Kaneda Y, Fujii A, Ohmori T: The hypothalamic-pituitary-adrenal axis in chronic schizophrenic patients long-term treated with neuroleptics. Prog Neuro-Psychopharmacol Biol Psychiatry 2002;26: 935-938.
7. Van Cauter, E, Linkowski P, Kerkhofs M, Hubain P, L'Hermite-Baleriaux M, Leclercq R, Brasseur M, Copinschi G, Mendelwicz J: Circadian and sleep-related endocrine rhythms in schizophrenia. Arch Gen Psychiatry 1991;48:348-356.
8. Rao M, Strebel B, Halaris A, Gross G, Braunig P, Marler M: Circadian rhythm of vital signs, norepinephrine, epinephrine, thyroid hormones and cortisol in schizophrenia. Psychiatry Res 1995;57: 21-39.
9. Elman I, Adler CM, Malhotra AK, Bir C, Pickar D, Breier A: Effect of acute metabolic stress on pituitary-adrenal axis activation in patients with schizophrenia. Am J Psychiatry 1998;155:979-981.
10. Meador-Woodruff JH, Greden JF: Effects of psychotropic medications on hypothalamic-pituitary-adrenal regulation. Neurol Clin 1988;6:225-234.
11. Pariante CM: Pituitary volume in psychosis: the first review of the evidence. J Psychopharmacol 2008;22(2 suppl):76-81.
12. Sharma R, Pandey G, Janicak P, et al: The effect of diagnosis and age on the DST: a meta-analytic approach. Biol Psychiatry 1998;24:555-568.
13. Yehuda R, Southwick S, Nussbaum G, et al: Low urinary cortisol excretion in patients with posttraumatic stress disorder. J Nerv Ment Dis 1990;178:366-369.
14. de Leon M, McRae T, Tsai J, et al: Abnormal cortisol response in Alzheimer's disease linked to hippocampal atrophy. Lancet 1988;ii:391-92.
15. D'Souza DC, Abi-Saab WM, Madonick S, et al: Delta-9-tetrahydrocannabinol effects in schizophrenia: implications for cognition, psychosis, and addiction. Biol Psychiatry 2005;57:594-608.
16. Lammers C, Garcia Boreguero D, Schmider J, et al: Combined dexamethasone/corticotrophin releasing hormone test in patients with schizophrenia and in normal controls. Biol Psychiatry 1995;38:803-807.
17. Goldman MB, Blake K, Marks RC, Hedeker D, Luchins DJ: Association of nonsuppression on the DST with primary polydipsia in chronic schizophrenia. Am J Psychiatry 1993;150:653-655.
18. Goldman MB, Robertson GL, Luchins DJ, Hedeker P, Pandey GN: Psychotic exacerbations and enhanced vasopressin secretion in schizophrenic patients with hyponatremia and polydipsia. Arch Gen Psychiatry 1997;54:443-449.
19. Hundt W, Kellner M, Wiedemann K: Neuroendocrine effects of a short-term osmotic stimulus in patients with chronic schizophrenia. World J Biol Psychiatry 2001;2:27-33.
20. Jansen LMC, Gispen-de Wied CC, Kahn RS: Selective impairments in the stress response in schizophrenic patients. Psychopharmacology 2000;149:319-325.
21. Kendler KS, Weitzman RE, Rubin R: Lack of arginine vasopressin response to central dopamine blockade in normal adults. J Clin Endocrinol Metab 1978;47:204-207.
22. Nomura K, Kurimoto F, Demura H, Sakurai, H, Nomura T, Zibiki K, Naruse M, Kanai N, Shizume K: The effects of metoclopramide on plasma vasopressin in man. Clinical Endocrinol 1984;21:117-121.
23. Norbiato G, Bevilacqua M, Chebat E, Bertora P, Cavaiani P, Baruto C, Fumagalli S, Raggi U: Metoclopramide increases vasopressin secretion. J Clin Endocrinol Metab 1986;63:747-750.
24. Seki K, Kato T, Sekiya S: Corticotrophin and vasopressin responses to metoclopramide in patients with hypothalamic amenorrhoea. Clin Endocrinol 1997;46:203-207.
25. Walsh P, Spelman L, Sharifi N, Thakore JH: Male patients with paranoid schizophrenia have greater ACTH and cortisol secretion in response to metoclopramide-induced AVP release. Psychoneuroendocrinology 2005;30:431-437.
26. Rabadan-Diehl C, Aguilera G: Glucocorticoids increase vasopressin V1b receptor coupling to phospholipase C. Endocrinology 1998;139:3220-3226.
27. Marcelis M, Cavalier E, Gielen J, Delespaul P, Van Os J: Abnormal response to metabolic stress in schizophrenia: marker of vulnerability or acquired sensitization? Psychol Med 2004;34:1103-1111.
28. Myin-Germeys I, Marcelis M, Krabbendam L, Delespaul P, van Os J: Subtle fluctuations in psychotic phenomena as functional states of abnormal dopamine reactivity in individuals at risk. Biol Psychiatry 2005;58:105-110.
29. Brunelin J, d'Amato T, Van OS J, Dalery J, Suaud-Chagny MF, Saoud M: Serotonergic response to stress: a protective factor against abnormal dopaminergic reactivity in schizophrenia? Eur Psychiatr 2007;22:362-364.
30. Perlman WR, Webster MJ, Kleinman JK, Weickert CS: Reduced glucocorticoid and estrogen receptor messenger ribonucleic acid levels in the amygdala of patients with major mental illness. Biol Psychiatry 2004;56:844-852.
31. Xing GQ, Russell S, Webster MJ, Post RM: Decreased expression of mineralocorticoid receptor mRNA in the prefrontal cortex in schizophrenia and bipolar disorder. Int J Neuropsychopharmacol 2004;7:143-153.
32. Webster M, O'Grady J, Orthmann C, et al: Decreased glucocorticoid receptor mRNA levels in individuals with depression, bipolar disorder and schizophrenia. Schizophrenia Res 2000;41:111.
33. Thakore JH, Dinan TG: Growth hormone secretion: the role of glucocorticoids. Life Sci 1994;14:1083-1099.
34. Thakore JH, Dinan TG: Are blunted dexamethasone-induced growth hormone responses specific for depression? Psychol Med 1996;26:1053-1059.
35. Sapolsky RM. Stress and plasticity in the limbic system. Neurochem Res 2003;28:1735-1742.
36. Geuze E, Vermetten E, Bremner JD: MR-based in vivo hippocampal volumetrics: 2. Findings in neuropsychiatric disorders. Mol Psychiatry 2005;10:160-184.
37. Steen RG, Mull C, McClure R, Hamer RM, Lieberman JA: Brain volume in first-episode schizophrenia: systematic review and meta-analysis of magnetic resonance imaging studies. Br J Psychiatry 2006;188:510-518.
38. Antonova E, Sharma T, Morris R, Kumari V: The relationship between brain structure and neurocognition in schizophrenia: a selective review. Schizophr Res 2004;70:117-145.
39. McNeil TF, Cantor-Graae E, Weinberger DR: Relationship of obstetric complications and differences in size of brain structures in monozygotic twin pairs discordant for schizophrenia. Am J Psychiatry 2000;157:203-212.
40. van Erp TG, Saleh PA, Huttunen M, et al. Hippocampal volumes in schizophrenic twins. Arch Gen Psychiatry 2004;61:346-353.
41. Meador CK, Liddle GW, Island DP, et al: Cause of 'Cushing's syndrome' in patients with tumors arising from non-endocrine tissue. J Clin Endocrinol Metab 1962;22:693-703.
42. Orth DN: Ectopic hormone production; in Felig P, Baxter JD, Broadus AE, et al (eds): Endocrinology and Metabolism, ed 2. New York, McGraw-Hill, 1987, pp 1692-1735.
43. Rebuffe-Scrive M, Lundholm K, Bjorntorp P: Glucocorticoid binding of human adipose tissue. Eur J Clin Invest 1985;15:267-272.
44. Pedersen SB, Jonier M, Richelsen B: Characterisation of regional and gender differences in glucocorticoid receptors and lipoprotein lipase activity in human adipose tissue. J Clin Endocrinol Metab 1994;78:1354-1359.
45. Santosa S, Jensen MD: Why are we shaped differently and why does it matter? Am J Physiol 2008;295:E531-E353.
46. Paolisso G, Tataranni PA, Foley JE, Bogardus C, Howard BV, Ravussin E: A high concentration of fasting plasma non-esterified fatty acids is a risk factor for the development of NIDDM. Diabetologia 1995;38:1213-1217.
47. Piro S, Spampinato D, Spadaro L, Oliveri CE, Purrello F, Rabuazzo AM: Direct apoptotic effects of free fatty acids on human endothelial cells. Nutr Metab Cardiovasc Dis 2008;18:96-104.
48. Pirro M, Mauriege P, Tchernof A, Cantin B, Dagenais GR, Despres JP, Lamarche B: Plasma free fatty acid levels and the risk of ischemic heart disease in men: prospective results from the Quebec Cardiovascular Study. Atherosclerosis 2002;160:377-384.
49. Prentki M: New insights into pancreatic beta-cell metabolic signaling in insulin secretion. Eur J Endocrinol 1996;134:272-286.
50. Bjorntorp P: The regulation of adipose tissue distribution in humans. Int J Obes 1996;20:291-302.
51. Ottoson M, Vikman-Adolfson K, Enerback S, Olivecrona G, Bjorntorp P: The effects of cortisol on the regulation of lipoprotein lipase activity in human adipose tissue. J Clin Endocrinol Metab 1994;79:820-825.
52. Lupien SJ: Stress and schizophrenia: the importance of cognition. Biol Psychiatry 2000;48:1119-1120.
53. Dickerson SS, Kemeny ME: Acute stressors and cortisol responses: a theoretical integration and synthesis of laboratory research. Psychol Bull 2004;130:355-391.
54. Seematter G, Binnert C, Tappy L: Stress and metabolism. Metab Syndr Relat Disord 2005;3:8-13.
55. Chandola T, Britton A, Brunner E, Hemingway H, Malik M, Kumari M, Badrick E, Kivimaki M, Marmot M: Work stress and coronary heart disease: what are the mechanisms? Eur Heart J 2008;29:640-648.
56. Syed AA, Redfern CP, Weaver JU: In vivo and in vitro glucocorticoid sensitivity in obese people with cushingoid appearance. Obesity (Silver Spring) 2008;16:2374-2378.
57. Iwasaki Y, Takayasu S, Nishiyama M, Tsugita M, Taguchi T, Asai M, Yoshida M, Kambayashi M, Hashimoto K: Is the metabolic syndrome an intracellular Cushing state? Effects of multiple humoral factors on the transcriptional activity of the hepatic glucocorticoid-activating enzyme (11beta-hydroxysteroid dehydrogenase type 1) gene. Mol Cell Endocrinol 2008;285:10-18.
58. Walker E, Mittal V, Tessners K: Stress and the hypothalamic pituitary adrenal axis in the developmental course of schizophrenia. Annu Rev Clin Psychol 2008;4:189-216.